Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma

Sun Min Lim, Hyunki Kim, Beodeul Kang, Hyo Song Kim, SunYoung Rha, Sung Hoon Noh, WooJin Hyung, Jae Ho Cheong, Hyoung Il Kim, Hyuncheol Chung, Mijin Yun, Arthur Cho, Minkyu Jung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max  = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalAnnals of Nuclear Medicine
Volume30
Issue number4
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Neuroendocrine Carcinoma
Fluorodeoxyglucose F18
Positron-Emission Tomography
Glycolysis
Stomach
Carcinoma
Neoplasm Metastasis
Tumor Burden
Stomach Neoplasms
Neoplasms
Survival
Metabolic Diseases

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Lim, Sun Min ; Kim, Hyunki ; Kang, Beodeul ; Kim, Hyo Song ; Rha, SunYoung ; Noh, Sung Hoon ; Hyung, WooJin ; Cheong, Jae Ho ; Kim, Hyoung Il ; Chung, Hyuncheol ; Yun, Mijin ; Cho, Arthur ; Jung, Minkyu. / Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma In: Annals of Nuclear Medicine. 2016 ; Vol. 30, No. 4. pp. 279-286.
@article{50a9bd2ac85c4ad0b234f3d9edbe4ca6,
title = "Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma",
abstract = "Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 {\%} CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 {\%} CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max  = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.",
author = "Lim, {Sun Min} and Hyunki Kim and Beodeul Kang and Kim, {Hyo Song} and SunYoung Rha and Noh, {Sung Hoon} and WooJin Hyung and Cheong, {Jae Ho} and Kim, {Hyoung Il} and Hyuncheol Chung and Mijin Yun and Arthur Cho and Minkyu Jung",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s12149-016-1059-x",
language = "English",
volume = "30",
pages = "279--286",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "4",

}

Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma . / Lim, Sun Min; Kim, Hyunki; Kang, Beodeul; Kim, Hyo Song; Rha, SunYoung; Noh, Sung Hoon; Hyung, WooJin; Cheong, Jae Ho; Kim, Hyoung Il; Chung, Hyuncheol; Yun, Mijin; Cho, Arthur; Jung, Minkyu.

In: Annals of Nuclear Medicine, Vol. 30, No. 4, 01.05.2016, p. 279-286.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma

AU - Lim, Sun Min

AU - Kim, Hyunki

AU - Kang, Beodeul

AU - Kim, Hyo Song

AU - Rha, SunYoung

AU - Noh, Sung Hoon

AU - Hyung, WooJin

AU - Cheong, Jae Ho

AU - Kim, Hyoung Il

AU - Chung, Hyuncheol

AU - Yun, Mijin

AU - Cho, Arthur

AU - Jung, Minkyu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max  = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.

AB - Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max  = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.

UR - http://www.scopus.com/inward/record.url?scp=84964291949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964291949&partnerID=8YFLogxK

U2 - 10.1007/s12149-016-1059-x

DO - 10.1007/s12149-016-1059-x

M3 - Article

VL - 30

SP - 279

EP - 286

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 4

ER -